Novartis expands in radio-oncology again with $1.3bn Artios alliance

The collaboration will focus on combining Artios’ DNA damage response (DDR) drug candidates with Novartis’ radioligand therapies, which consist of tumour-targeting molecules carrying radioactive isotopes that can deliver a cell-killing dose of radiation to malignant cells. Novartis has made radioligands one of four pillars of its cancer business, along with cell and gene therapy.
Read more...

;